

Scan & Share

**Apollo Hospitals Enterprise Limited**  
Corporate Identity Number : L85110TN1979PLC008035  
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaiapuram, Chennai - 28, Tamil Nadu  
Tel. +91 -44 -28290956, Fax +91 -44 -28290956  
Email: investor.relations@apollohospitals.com, Website : www.apollohospitals.com



**Extract of Statement of Unaudited Financial Results for the Three & Nine Months Ended December 31, 2020**

(Rs. in Lakhs, except  
per share data)

Particulars	Standalone						Consolidated					
	Three months ended 31/12/2020	Preceding Three months ended 30/09/2020	Corresponding Three months ended 31/12/2019	Year to date figures for current period ended 31/12/2020	Year to date figures for previous period ended 31/12/2019	Previous year ended 31/03/2020	Three months ended 31/12/2020	Preceding Three months ended 30/09/2020	Corresponding Three months ended 31/12/2019	Year to date figures for current period ended 31/12/2020	Year to date figures for previous period ended 31/12/2019	Previous year ended 31/03/2020
Total Income from Operations (net)	2,36,794	2,41,924	2,53,251	6,75,038	7,23,397	9,80,534	2,76,534	2,77,204	2,92,140	7,71,660	8,34,739	11,27,377
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	15,530	3,953	14,564	891	40,680	51,801	18,534	3,015	14,530	(5,153)	37,335	45,869
Net Profit / (Loss) for the period (before Tax, after Exceptional and/or Extraordinary Items)	15,530	3,844	14,564	782	40,680	68,236	18,534	6,560	14,530	(1,609)	37,335	65,699
Net profit / (Loss) for the period after tax (after Exceptional and Extraordinary items)	10,622	3,252	9,475	(1,037)	26,465	47,025	13,416	5,899	8,995	(3,312)	22,220	43,180
Total Comprehensive Income for the period (comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)	10,555	2,824	9,395	(1,693)	26,489	47,100	13,384	5,549	8,900	(3,848)	21,716	43,120
Paid up Equity Share Capital (Face value of Rs.5/- each)						6,956						6,956
Reserves (excluding Revaluation Reserve)						3,91,897						3,26,209
Networth						3,85,570						
Earnings Per Share of Rs. 5/- each	*7.64	*2.34	*6.81	*(0.74)	*19.02	33.80	*9.38	*4.33	*6.62	*(1.26)	*16.93	32.70
Diluted	*7.64	*2.34	*6.81	*(0.74)	*19.02	33.80	*9.38	*4.33	*6.62	*(1.26)	*16.93	32.70

**Notes:** 1. The above is an extract of the detailed format of financial results (both standalone and consolidated) for three and nine months ended December 31, 2020 filed with stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the stock exchange websites www.nseindia.com and www.bseindia.com and also the company's website www.apollohospitals.com.

2. The unaudited financial results (Standalone and Consolidated) of Apollo Hospitals Enterprise Limited ("the Company") for the three and nine months ended December 31, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on February 11, 2021 and February 12, 2021 respectively and have been subjected to limited review by the statutory auditors.

3. The Company completed a Qualified Institutional Equity placement in January 2021, allotting an additional 46,59,498 equity shares at a price of Rs 2.511 per share (face value Rs 5/- each) aggregating to a sum of Rs. 116,999.99 lakhs pursuant to the approval accorded by the members through Postal Ballot to raise equity proceeds upto a sum of Rs. 150,000 lakhs.

**Standalone**  
The Scheme of Arrangement (the Scheme) for transfer of front-end retail pharmacy business included in the standalone pharmacy segment ("Divestment Business") to Apollo Pharmacies Limited ("APL" or "Transferee Company"), a wholly owned subsidiary of Apollo Medicals Private Limited ("AMPL") was effective September 1, 2020 ("the effective date").

Consequently, retail pharmacy segment as presented in these financial results include transactions of the divestment business till the effective date. Post the disposal of the divestment business, the Company has identified Pharmacy Distribution as a new segment with effect from September 1, 2020. The Company thereafter has identified Healthcare and Pharmacy Distribution as its operating and reportable segments. Healthcare segment represents hospitals and hospital based pharmacies. Pharmacy distribution segment represents the business of procurement and distribution of pharmaceutical, fast moving consumer goods (FMCG) and private label products.

The figures for the three and nine months ended December 31, 2020 are not comparable with the figures for the preceding three months ended September 30, 2020, corresponding three months ended December 31, 2019 and the year to date figures for the previous period ended December 31, 2019.

**Consolidated**

The Scheme of Arrangement (the Scheme) for transfer of front-end retail pharmacy business included in the standalone pharmacy segment ("Divestment Business") to Apollo Pharmacies Limited ("APL" or "Transferee Company"), a wholly owned subsidiary of Apollo Medicals Private Limited ("AMPL") for an overall cash consideration of Rs.52,780 lakhs was approved by the National Company Law Tribunal vide their Order dated August 3, 2020.

Pursuant to the Scheme becoming effective, the Company invested Rs.3,650 lakhs and its ownership interest in AMPL changed to 25.50%, resulting in loss of control with effect from September 1, 2020. Net gain associated with the loss of control of Rs. 3,544 lakhs has been included under Exceptional Items.

Retail pharmacy segment as presented in these financial results, include transactions of the divestment business till the effective date. Post the disposal of the divestment business, the Company has identified Pharmacy Distribution as a new segment with effect from September 1, 2020. The Company thereafter has identified Healthcare, Pharmacy Distribution, Clinics and others as its operating and reportable segments. Healthcare segment represents hospitals and hospital based segment includes revenue, assets and liabilities of components not engaged in any of the above segments.

The figures for the three and nine months ended December 31, 2020 are not comparable with the figures for the preceding three months ended September 30, 2020, corresponding three months ended December 31, 2019 and the year to date figures for the previous period ended December 31, 2019.

5. On 7th January 2021, the Company completed the acquisition of an 1% additional stake in Medics International Lifesciences Limited ("Medics") which runs a 330 bedded hospital in Lucknow. Consequently, Medics will become a subsidiary of the Company with effect from the date of acquisition and no adjustment for the same has been considered in the results for the current period.

6. The proposed acquisition of an additional 50% stake in Apollo Gleneagles Hospital Ltd, Kolkata is yet to be completed pending closure of certain formalities. Consequently to the execution of the Share Purchase Agreement between the Company, Gleneagles Development Pte Ltd and Apollo Gleneagles Hospital Limited, the Company has executed a Second Amendment Agreement extending the Long Stop Date to 28th February, 2021 for consummating the transaction. No effect of this acquisition has therefore been given in these financial results.

7. The Board of Directors through a circular resolution, approved the revised proposal in compliance with Section 233 of the Companies Act, 2013 to proceed with an application to the Regional Director, Southern Region, Ministry of Corporate Affairs for approving the Scheme of Merger of the following wholly owned subsidiary companies with the Company, subject to completion of necessary formalities and obtaining requisite approvals instead of filing applications with NCLT seeking dispensation of convening shareholders / creditors meetings of the Company.

\* Apollo Home Healthcare (India) Limited and  
\* Western Hospitals Corporation Private Limited

8. The Management has considered the possible effects if any that may result from the pandemic relating to COVID-19 on recoverability of receivables, Property, plant & equipment including Capital work in progress and certain investments. The Company has considered internal and external information up to the date of approval of these financial results. Based on the current indicators of future economic conditions, the Company expects to recover the carrying amount of these assets. The actual outcome of these assumptions and estimates may vary in future due to the impact of the pandemic. The Company will continue to monitor any material changes to future economic conditions and the consequent impact on its business, if any, and any significant impact of these changes would be recognized in the financial results as and when these material changes to economic conditions arise.

9. The listed non-convertible debentures of the Company aggregating to Rs. 20,000 lakhs as on December 31, 2020 are secured by way of first charge on the Company's properties and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.

10. The proceedings initiated against Imperial Hospitals and Research Centre Limited, a subsidiary company, by the Government of Karnataka alleging non-compliance of certain conditions associated with the allotment of land, has been stayed by the Honorable High Court of Karnataka on April 27, 2018. Based on legal opinion, the management is of the opinion that it has adequate grounds to demonstrate compliance with applicable conditions and therefore the proceedings are not sustainable. There have been no further developments during this quarter.

Place : Chennai  
Date : 12th February, 2021

for APOLLO HOSPITALS ENTERPRISE LIMITED  
**DR. PRATHAP C REDDY**  
Executive Chairman



for APOLLO HOSPITALS ENTERPRISE LIMITED  
**DR. PRATHAP C REDDY**